|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
|
|---|---|---|---|
| Cash Flows from Operating Activities: | |||
| Net loss | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation | |||
| Stock option cancellations | |||
| Issuance of common stock for equity line of credit commitment fee | |||
| Depreciation and amortization expense | |||
| Issuance of common stock, net of discount for lack of marketability | |||
| Warrant expense - termination agreement | |||
| Warrant liability - mark-to-market | |||
| Changes in operating assets - (increase)/decrease: | |||
| Other current assets | |||
| Changes in operating liabilities - increase/(decrease): | |||
| Accounts payable | |||
| Accrued expenses | |||
| Net cash used in operating activities | |||
| Cash Flows from Investing Activities: | |||
| Purchase of property and equipment | |||
| Net cash used in investing activities | |||
| Cash Flows from Financing Activities (increase/decrease): | |||
| Gross proceeds from issuance of common stock | |||
| Direct financing costs for issuance of common stock | |||
| Gross proceeds from warrant inducement | |||
| Direct transaction costs for warrant inducement | |||
| Gross proceeds from issuance and exercises of pre-funded warrants | |||
| Direct financing costs for issuance of pre-funded warrants | |||
| Gross proceeds from issuance of common stock, pre-funded and common warrants | |||
| Payment of issuance costs for financing | |||
| Direct transaction costs for issuance of common stock, pre-funded and common warrants | |||
| Payment of issuance costs for registration statement | |||
| Private Placement | |||
| Total payment of issuance costs for registration statement | |||
| Gross proceeds from exercise of warrants | |||
| Proceeds from sales of common stock | |||
| Issuance of convertible debt | |||
| Issuance of common stock from IPO | |||
| Payment of issuance costs for IPO | |||
| Net cash provided by financing activities | |||
| Net change in cash and cash equivalents | |||
| Cash and cash equivalents, at beginning of period | |||
| Cash and cash equivalents, at end of period | |||
| Non-cash financing activities: | |||
| Warrants issued for debt issuance costs | |||
| Recognition of deferred financing costs associated with issuance of common stock | |||
| Proceeds from cashless exercise of warrants | |||
| Fair value of warrants issued for issuance costs as part of IPO | |||
| Holdback of IPO proceeds | |||
| Convertible notes converted into common stock (in shares) | |||
| Warrants issued for equity issuance costs | |||
| Convertible notes converted into common stock | |||
| Settlement/conversion to common shares for debt issuance costs | |||
| Issuance of Common Stock for Extinguishment of Convertible Debt | |||
| Total settlement/conversion to common shares for debt issuance costs |
Loading...